Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
Glucotrack (GCTK) delivers innovative diabetes management solutions through non-invasive and implantable glucose monitoring technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and market developments.
Access real-time information about regulatory milestones, product certifications, and strategic partnerships. Our curated feed includes earnings reports, clinical trial outcomes, and technology updates directly impacting GCTK's position in the medical device sector.
Key coverage areas include FDA/EU regulatory progress, implantable CBGM system trials, and commercial expansion initiatives. Bookmark this page for streamlined tracking of Glucotrack's progress in revolutionizing blood glucose measurement through cutting-edge ultrasound and electromagnetic technologies.
Glucotrack (Nasdaq: GCTK) entered a securities purchase agreement dated Dec 30, 2025, with a single institutional investor to sell 1,033,591 common shares (or equivalents) plus warrants to buy up to 2,067,182 shares at a combined effective price of $3.87 per share, for aggregate gross proceeds of approximately $4.0 million before fees.
The warrants carry a $3.87 exercise price, expire five years from initial exercise, and are not exercisable until shareholder approval. Closing is expected on or about Dec 31, 2025. Proceeds are planned for working capital and general corporate purposes. Curvature Securities is sole placement agent. The company agreed to file resale registration within 15 days of closing and use efforts to have it effective within 45 days.
Glucotrack (Nasdaq: GCTK) reported third-quarter 2025 results and corporate updates on November 13, 2025. The company secured new financing, increasing cash to $7.9 million as of September 30, 2025, and expects that cash to fund operations through Q1 2026. Glucotrack received $3.0 million under a Note Purchase Agreement and established an equity line of credit up to $20.0 million. Clinical progress includes initiation of a one-year, multicenter feasibility study in Australia and planned submission of an IDE to FDA in Spring 2026. Management added Dr. Usman Latif to its clinical advisory team. For nine months ended September 30, 2025, the company reported a net loss of $15.8 million compared with $12.5 million year‑ago.
Glucotrack (Nasdaq: GCTK) reconvened its Special Meeting of Shareholders for November 7, 2025 at 12:00 p.m. ET to vote on a $20 million Purchase Agreement with Sixth Borough Capital Fund LP that would permit the company, under NASDAQ Listing Rule 5635(d), to issue more than 20% of its outstanding common stock. Shareholders of record as of September 23, 2025 are entitled to vote. The Board unanimously recommends voting FOR all proposals and encourages holders to vote online, by phone, or by returning proxy cards so votes are tabulated before the meeting. Further details are available in the company’s definitive proxy filed with the SEC on October 3, 2025. Contact information for voting assistance is provided.
Glucotrack (Nasdaq: GCTK) named Usman Latif, MD, MBA to its clinical advisory team on October 29, 2025 to guide development of integrated glucose monitoring for painful diabetic neuropathy (PDN) and epidural monitoring.
Dr. Latif is an anesthesiologist and neuromodulation expert with academic appointments and clinical fellowships at institutions including Johns Hopkins, Harvard/Mass General, Yale, and University of Kansas. The company said it completed a long-term preclinical study showing feasibility and safety of epidural glucose monitoring and continues development of its implantable CBGM system with 3-year sensor longevity.
PDN affects roughly one-fifth of >38 million Americans with diabetes (~7 million people). The CBGM is an investigational device and Glucotrack highlighted regulatory, clinical trial, and financing risks.
Glucotrack (Nasdaq: GCTK) will hold a Special Meeting of Shareholders on October 31, 2025 at 12:00 p.m. ET for a shareholder vote on an Equity Purchase Agreement with Sixth Borough Capital. Shareholders of record as of September 23, 2025 are eligible to vote. The Board of Directors unanimously recommends voting "FOR" all proposals.
Shareholders are urged to vote early by telephone, online, or by returning a signed proxy card. The Company filed its definitive proxy statement with the SEC on October 3, 2025, and additional information is available at www.sec.gov. Voting assistance is available from proxy solicitors Sodali & Co. at 1-888-777-2094 or GCTK.info@investor.sodali.com.
Glucotrack (Nasdaq: GCTK), a medical technology company specializing in diabetes technologies, has announced its participation in the upcoming Q3 Virtual Investor Summit. Paul V. Goode, PhD, the company's President and CEO, will lead the presentation on Tuesday, September 16, 2025, at 1:30 PM ET.
The event will include a company presentation and one-on-one meetings with investors, providing an opportunity for stakeholders to learn more about Glucotrack's developments in diabetes technology.
Glucotrack (NASDAQ:GCTK), a medical technology company developing novel diabetes technologies, reported significant progress in Q2 2025. The company is preparing to launch a multicenter feasibility study of its fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025, followed by an FDA IDE submission in Q4 2025.
Key developments include strengthening the leadership team with Dr. David Hirsh as Medical Director-Cardiology and Dr. Victoria Carr-Brendel joining the Board. Clinical data presented at the ADA conference showed excellent accuracy with a MARD of 7.7% and 99% data capture rate. The company reported $9.6 million in cash as of June 30, 2025, sufficient to fund operations through 2025.
Financial results showed R&D expenses of $5.0 million and net loss of $11.6 million for H1 2025. The company strengthened its capital structure by repurchasing Series A Warrants to eliminate warrant liability and dilution concerns.
Glucotrack (NASDAQ:GCTK) has appointed Dr. David S. Hirsh as Medical Director of Cardiology to support the development of their Continuous Blood Glucose Monitor (CBGM). Dr. Hirsh, an experienced cardiac electrophysiologist from Harbin Clinical Cardiology Rome, brings extensive expertise in interventional cardiology procedures.
The appointment strengthens Glucotrack's clinical leadership as they advance their long-term implantable CBGM system, which is designed for up to three years of continuous monitoring. Unlike traditional monitors that measure glucose from interstitial fluid, Glucotrack's device measures directly from blood, aiming to provide real-time readings without lag time. The system features a unique intravascular placement approach and requires no wearable component.
Glucotrack (NASDAQ:GCTK) announced its participation in the 2025 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting from August 8-11, 2025 in Phoenix, AZ. The company will showcase its innovative Continuous Blood Glucose Monitor (CBGM) at Booth #1724 and present a scientific poster on endocrinologist perspectives regarding implantable monitoring technology.
Glucotrack's CBGM technology represents a significant advancement in diabetes management, offering a fully implantable solution that lasts up to three years. Unlike traditional CGMs that measure glucose in interstitial fluid through skin-worn devices, this system measures glucose directly from blood without requiring any external wearables. The company is preparing to begin its long-term early feasibility study following successful initial clinical validation.
Glucotrack (Nasdaq: GCTK) has announced the successful repurchase of over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025. The company repurchased approximately 49,700 Series A Warrants using existing cash, with about 4,300 warrants remaining outstanding. The warrants were originally issued as part of a $10M Public Offering in November 2024.
The repurchase is part of Glucotrack's capital formation strategy and demonstrates confidence in its development of a long-term implantable continuous blood glucose monitoring system for diabetes patients. The company's Series B Warrants were previously converted to common stock, as reported in Q1 2025.
FAQ
What is the current stock price of Glucotrack (GCTK)?
What is the market cap of Glucotrack (GCTK)?
